BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning.
SRPT has been the topic of several other reports. BTIG Research began coverage on Sarepta Therapeutics in a report on Friday, June 15th. They issued a buy rating and a $120.00 target price on the stock. HC Wainwright lifted their target price on Sarepta Therapeutics from $96.00 to $267.00 and gave the stock a buy rating in a report on Tuesday, June 19th. Goldman Sachs Group lifted their target price on Sarepta Therapeutics from $84.00 to $127.00 and gave the stock a buy rating in a report on Friday, May 18th. Morgan Stanley boosted their price objective on Sarepta Therapeutics from $91.00 to $163.00 and gave the stock an equal weight rating in a research note on Wednesday, June 20th. Finally, Nomura boosted their price objective on Sarepta Therapeutics from $131.00 to $205.00 and gave the stock a buy rating in a research note on Thursday, June 21st. Three analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $154.21.
Shares of SRPT stock opened at $152.76 on Friday. Sarepta Therapeutics has a 12-month low of $42.97 and a 12-month high of $176.50. The company has a current ratio of 10.88, a quick ratio of 9.89 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $10.02 billion, a PE ratio of -93.15 and a beta of 1.30.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.99). Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The firm had revenue of $73.53 million during the quarter, compared to the consensus estimate of $71.53 million. During the same period last year, the firm posted ($0.48) earnings per share. The company’s revenue for the quarter was up 110.0% compared to the same quarter last year. analysts predict that Sarepta Therapeutics will post -3.69 EPS for the current year.
In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total transaction of $9,775,500.00. Following the completion of the transaction, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Douglas S. Ingram bought 16,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the transaction, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at $50,010,055. The disclosure for this purchase can be found here. Insiders have sold 158,782 shares of company stock worth $21,237,444 over the last three months. 7.90% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the business. Bain Capital Public Equity Management LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $9,755,000. Public Employees Retirement System of Ohio purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $5,224,000. Nomura Holdings Inc. boosted its position in shares of Sarepta Therapeutics by 108.1% during the second quarter. Nomura Holdings Inc. now owns 18,400 shares of the biotechnology company’s stock valued at $2,432,000 after buying an additional 245,231 shares during the period. Verition Fund Management LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $415,000. Finally, Millennium Management LLC boosted its position in shares of Sarepta Therapeutics by 242.2% during the second quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock valued at $113,464,000 after buying an additional 607,588 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Further Reading: Understanding Average Daily Trade Volume
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.